Table 1.

Indications for wearable cardioverter defibrillator prescription in patients with myocarditis

WCD indication	n (%)
LVEF ≤ 35 ± prior VF/VT ± cardiac sarcoidosis/giant cell myocarditis	41 (69.5)
VT/VF during hospitalization and LVEF > 35%	6 (10.2)
Sarcoidosis/giant cell and LVEF > 35%	2 (3.4)
LVEF 36–40%	4 (6.8)
Based on the physician's discretion	6 (10.2)

LVEF, left ventricular ejection fraction; VF, ventricular fibrillation; VT, ventricular tachycardia; WCD, wearable cardioverter defibrillator.